Blockchain Registration Transaction Record
Oragenics Partners with Sterling Pharma for Concussion Treatment Development
Oragenics announces manufacturing agreement with Sterling Pharma for ONP-002, targeting concussions, marking a key step towards Phase IIb trials. Learn more about this innovative treatment.

This news is significant as it highlights the advancement of a potential breakthrough treatment for concussions, a condition with limited therapeutic options. The partnership between Oragenics and Sterling Pharma Solutions not only accelerates the development of ONP-002 but also reinforces the importance of domestic manufacturing in the biotech sector. For patients suffering from concussions and related conditions, this represents hope for more effective treatments in the near future.
Blockchain | Details |
---|---|
Contract Address | 0xeA2912a8DA1CD48401b10cB283585874d98098F4 |
Transaction ID | 0xfd7087e749108c4a2888626820ab5bb1dff1f6757d415c4e3e04a319ff91bf45 |
Account | 0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20 |
Chain | polygon-main |
NewsRamp Digital Fingerprint | healxuGG-d01b509b9b9c1642125f2ecbf06bfbec |